Delta Sleep-Inducing Peptide (DSIP)

The speaker mentions that DSIP is part of a broader sleep protocol and can be paired with other peptides such as 'panelon' (likely referring to Pineal Peptide/Epitalon) or Epitalin. Specific stacking ratios or protocols are not detailed in the transcript but are offered as future content.

The speaker notes that in July 2026, the FDA advisory committee voted against recommending DSIP for compounding. However, they clarify this was a vote on regulatory frameworks, not a clinical verdict on efficacy, and no final rule has been issued at the time of filming.

The speaker warns that DSIP cannot compensate for a poor 'sleep foundation.' If the user has broken sleep hygiene habits (alcohol, late-night screen time, high cortisol, irregular bedtimes), the peptide will underdeliver or fail entirely. The compound is described as the 'last 20%' of the solution, not the primary driver.

The recommended protocol duration is a single month, with a maximum of six weeks. Users should not quit after one week if results are not immediate, nor should they use the peptide indefinitely as it may lead to dependency where sleep collapses upon cessation. The speaker advises stepping off after 30 days to assess baseline sleep without the compound.

The speaker recommends administering DSIP as a sublingual troche (lozenge) placed between the cheek and gum, split across both sides of the mouth to maximize surface area absorption. Injection and nasal sprays are discouraged due to inconsistent results. The dose should be taken approximately one hour before bed to allow for absorption before sleep onset.

The recommended dosage for DSIP is between 200 to 400 micrograms taken daily. The speaker advocates for the 'lowest effective dose' principle, advising users to find the smallest amount that moves their deep sleep metrics. Doses below this range may be ineffective, while doses above (e.g., >350 mcg) often result in morning grogginess or sedation rather than improved sleep quality.

The speaker clarifies that DSIP is not a sedative or sleep-onset agent but rather targets sleep architecture, specifically increasing deep sleep brain wave activity (delta waves). It does not 'knock out' the user; instead, it modifies the structure of sleep cycles. Effectiveness should be measured by objective data from sleep trackers (e.g., increased deep sleep minutes) rather than subjective feelings of drowsiness.